Intranasal LPS-mediated Parkinson's model challenges the pathogenesis of nasal cavity and environmental toxins

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  He, Qing ^a,b   Yu, Wenbo ^a,c   Wu, Jianjun ^a   Chen, Chan ^a   Lou, Zhiyin ^d   Zhang, Qiong ^a   Zhao, Jian ^a   Wang, Jian ^a   Xiao, Baoguo ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; ENDOTOXIN; LIPOPOLYSACCHARIDE; NEUROTOXIN; DANGEROUS GOODS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINERGIC NERVE CELL; EXPOSURE; FEMALE; GLIA; HYPOKINESIA; IMMUNE RESPONSE; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; MOUSE MODEL; NERVE DEGENERATION; NONHUMAN; NOSE CAVITY; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; SUBSTANTIA NIGRA; ANIMAL; CHEMICALLY INDUCED; DANGEROUS GOODS; DRUG EFFECTS; HUMAN; METABOLISM; MICROGLIA; OLFACTORY RECEPTOR; PATHOLOGY; TOXICITY;

ANIMALS; DOPAMINE; DOPAMINERGIC NEURONS; HAZARDOUS SUBSTANCES; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NASAL CAVITY; OLFACTORY RECEPTOR NEURONS; PARKINSON DISEASE;

EID: 84892569717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078418     Document Type: Article

References (37)

1. Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. N Engl J Med 339: 1044-1053. doi:10.1056/NEJM199810083391506. PubMed: 9761807.
2. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson's disease. Bioessays 24: 308-318. doi:10.1002/bies.10067. PubMed: 11948617.
3. Blandini F, Armentero MT (2012) Animal models of Parkinson's disease. FEBS J 279: 1156-1166. doi:10.1111/j.1742-4658.2012.08491.x. PubMed: 22251459.
4. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66: 646-661. doi:10.1016/j.neuron.2010.04.034. PubMed: 20547124.
5. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934. doi:10.1016/j.cell.2010.02.016. PubMed: 20303880.
6. Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 3: S200-S204. doi:10.1016/S1353-8020(09)70814-4. PubMed: 20082990.
7. Dutta G, Zhang P, Liu B (2008) The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 22: 453-464. doi:10.1111/j.1472-8206.2008.00616.x. PubMed: 18710400.
8. Jung BD, Shin EJ, Nguyen XK, Jin CH, Bach JH et al. (2010) Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 56: 229-244. doi: 10.1016/j.neuint.2009.10.005. PubMed: 19850096.
9. Genc S, Zadeoglulari Z, Fuss SH, Genc K (2012) The adverse effects of air pollution on the nervous system. J Toxicol, 2012: 2012: 782462. PubMed: 22523490
10. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B et al. (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20: 6309-6316. PubMed: 10934283.
11. Clapp WD, Thorne PS, Frees KL, Zhang X, Lux CR et al. (1993) The effects of inhalation of grain dust extract and endotoxin on upper and lower airways. Chest 104: 825-830. doi:10.1378/chest.104.3.825. PubMed: 8365296.
12. Tonelli LH, Postolache TT (2010) Airborne inflammatory factors: "from the nose to the brain". Front Biosci (Schol Ed) 2: 135-152.
13. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211. doi:10.1016/S0197-4580(02)00065-9. PubMed: 12498954.
14. Doty RL (2008) The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63: 7-15. doi:10.1002/ana.21327. PubMed: 18232016.
15. Graff CL, Pollack GM (2005) Nasal drug administration: potential for targeted central nervous system delivery. J Pharmacol Sci 94: 1187-1195. doi:10.1002/jps.20318. PubMed: 15858850.
16. Bouet V, Boulouard M, Toutain J, Divoux D, Bernaudin M et al. (2009) The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat Protoc 4: 1560-1564. doi:10.1038/nprot.2009.125. PubMed: 19798088.
17. Wang YQ, Tu ZC, Xu XY, Li R, Qu WM et al. (2012) Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats. J Neurochem 120: 314-324. doi:10.1111/j.1471-4159.2011.07558.x. PubMed: 22035172.
18. Hong ZY, Huang ZL, Qu WM, Eguchi N (2005) Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. Acta Pharmacol Sin 26: 155-159. doi:10.1111/j.1745-7254.2005.00523.x. PubMed: 15663891.
19. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840. doi:10.1038/42166. PubMed: 9278044.
20. Moore JP, Sakkal S, Bullen ML, Kemp-Harper BK, Ricardo SD et al. (2013) A flow cytometric method for the analysis of macrophages in the vascular wall. J Immunol Methods.
21. Krueger S, Bernhardt A, Kalinski T, Baldensperger M, Zeh M et al. (2013) Induction of premalignant host responses by cathepsin x/z-deficiency in helicobacter pylori-infected mice. PLOS ONE 8: e70242. doi:10.1371/journal.pone. 0070242. PubMed: 23936173.
22. Izuta S, Ueki M, Ueno M, Nishina K, Shiozawa S et al. (2012) T-5224, a selective inhibitor of c-Fos/activator protein-1, attenuates lipopolysaccharide-induced liver injury in mice. Biotechnol Lett, 34: 2175-82. PubMed: 22927112.
23. Kurniati NF, van Meurs M, Vom Hagen F, Jongman RM, Moser J et al. (2012) Pleiotropic effects of angiopoietin-2 deficiency do not protect mice against endotoxin-induced acute kidney injury. Nephrol Dial Transplant.
24. Lim KL, Ng CH (2009) Genetic models of Parkinson disease. Biochim Biophys Acta 1792: 604-615. doi:10.1016/j.bbadis.2008.10.005. PubMed: 19000757.
25. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R et al. (2003) Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 100: 8514-8519. doi:10.1073/pnas.1432609100. PubMed: 12824464.
26. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL et al. (2002) Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 962: 318-331. doi:10.1111/j.1749-6632.2002.tb04077.x. PubMed: 12076984.
27. Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D et al. (1994) Olfactory function in Parkinson's disease subtypes. Neurology 44: 266-268. doi:10.1212/WNL.44.2.266. PubMed: 8309571.
28. Friedman JH, Amick MM, Chou KL (2008) Rhinorrhea and olfaction in Parkinson disease. Neurology 70: 487-489. doi:10.1212/01.wnl. 0000279380.25130.ce. PubMed: 18250295.
29. Delayre-Orthez C, Becker J, de Blay F, Frossard N, Pons F (2005) Exposure to endotoxins during sensitization prevents further endotoxin-induced exacerbation of airway inflammation in a mouse model of allergic asthma. Int Arch Allergy Immunol 138: 298-304. doi: 10.1159/000088867. PubMed: 16220006.
30. Sultan S, Lefort JM, Sacquet J, Mandairon N, Didier A (2011) Acquisition of an olfactory associative task triggers a regionalized down-regulation of adult born neuron cell death. Front Neurosci 5: 52. PubMed: 21577252.
31. Funabe S, Takao M, Saito Y, Hatsuta H, Sugiyama M et al. (2012) Neuropathologic analysis of Lewy-related alpha-synucleinopathy in olfactory mucosa. Neuropathology.
32. Pignatelli A, Borin M, Fogli Iseppe A, Gambardella C, Belluzzi O (2013) The h-current in periglomerular dopaminergic neurons of the mouse olfactory bulb. PLOS ONE 8: e56571. doi:10.1371/journal.pone.0056571. PubMed: 23418585.
33. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69. doi: 10.1038/nrn2038. PubMed: 17180163.
34. Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39: 151-170. doi:10.1016/0306-4522(90)90229-W. PubMed: 2089275.
35. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (8): 1437-1448. doi:10.1093/brain/ 122.8.1437.
36. Lunardi G, Galati S, Tropepi D, Moschella V, Brusa L et al. (2009) Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 15: 383-389. doi:10.1016/j.parkreldis.2008.10.001. PubMed: 19010710.
37. Pérez-Otaño I, Oset C, Luquin MR, Herrero MT, Obeso JA et al. (1994) MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci Lett 175: 121-125. doi:10.1016/0304-3940(94)91094-4. PubMed: 7970192.